NCT04701918View on ClinicalTrials.gov

Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 4, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Metastatic Urothelial CarcinomaBladder Cancer
Interventions
DRUG

Pembrolizumab

Intravenous injection through a vein (IV) every 3 weeks

PROCEDURE

Cryoablation

Needle inserted through the skin and into the tumor using CT guidance

DRUG

Avelumab

Intravenous injection through a vein (IV) every 2 weeks

Trial Locations (2)

02114

RECRUITING

Massachusetts General Hospital Cancer Center, Boston

02215

RECRUITING

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
collaborator

Biocompatibles UK Ltd

INDUSTRY

lead

Massachusetts General Hospital

OTHER